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The development of needle-free vaccines is one of the recently defined “grand challenges in global health”
(H. Varmus, R. Klausner, R. Klausner, R. Zerhouni, T. Acharya, A. S. Daar, and P. A. Singer, Science
302:398–399, 2003). To explore whether a natural pathway to the inductive site of the mucosa-associated
lymphatic tissue could be exploited for atraumatic immunization purposes, replication-deficient viral vector
vaccines were sprayed directly onto the tonsils of rhesus macaques. Tonsillar immunization with viral vector
vaccines encoding simian immunodeficiency virus (SIV) antigens induced cellular and humoral immune
responses. Viral RNA levels after a stringent SIV challenge were reduced, providing a level of protection similar
to that observed after systemic immunization with the same vaccines. Thus, atraumatic oral spray immuni-
zation with replication-deficient vectors can overcome the epithelial barrier, deliver the vaccine antigen to the
mucosa-associated lymphatic tissue, and avoid induction of tolerance, providing a novel approach to circum-
vent acceptability problems of syringe and needle vaccines for children and in developing countries.
The first immunization studies in humans with viral vectors
encoding vaccine antigens have demonstrated induction of cel-
lular and humoral immune responses (7, 20, 29, 30, 33). Sev-
eral vector vaccines based on adenoviruses or poxviruses have
shown promising preclinical results and are currently at differ-
ent stages of clinical development for prophylactic or thera-
peutic use against infectious diseases or cancer.
In children, syringe and needle administration of vaccines
faces acceptability problems, while in developing countries the
inappropriate reuse of needles and syringes is associated with
an increased risk of infection. A noninvasive oral vaccination
strategy could greatly facilitate worldwide access to vaccines
by, for example, enabling trained teachers to administer the
vaccine. So far, only live attenuated vaccines have been used
for oral vaccination in humans. The efficacy of these vaccines
depends on subsequent replication and spread of the vaccines
in the gastrointestinal tract. Although highly efficient, the
spread of live attenuated vaccines to contact persons of the
vaccinees or reversion of the vaccines to virulent forms limits
the applicability of the live attenuated vaccine approach for
many infectious diseases. Oral vaccination with replication-
deficient viral vector vaccines might be able to substitute for
the live attenuated vaccines, but it is questionable whether they
can elicit substantial immune responses given that the excess
amount of antigens taken up as food on a regular basis mostly
leads to tolerance rather than immunity. In addition, if only the
superficial layers of the mucosa are transduced by the viral
vector vaccines, shedding of the transduced cells prior to ex-
pression of the vaccine antigen could be expected.
The epithelial barrier of the oral cavity to be passed by viral
vector vaccines consists of a multilayer, nonkeratinized squa-
mous epithelium. Below the epithelium, the oral cavity con-
tains the Waldeyer’s ring, an important member of the mucosa-
associated lymphatic tissue (MALT), including the lingual and
palatine tonsils. The crypts of these tonsils are lined by a
lymphoepithelium with interspersed M cells that facilitate con-
trolled entry of antigens through the epithelial barrier. Since
the oral mucosa and especially the crypt epithelium of the
tonsils are also rich in dendritic cells, delivery of the vaccine via
the tonsillar crypts could be a promising vaccination approach.
Administering simian immunodeficiency virus (SIV) onto
the tonsils of rhesus macaques led to efficient infection of
exposed animals, providing a valuable atraumatic mucosal
challenge model (36). Tonsillar delivery of live attenuated SIV
vaccines also provided protection against subsequent challenge
with homologous SIV and an SIV-human immunodeficiency
virus hybrid virus (35, 38). Since protection induced by these
live attenuated vaccines most likely has been due to systemic
spread of the vaccine virus, we now analyzed the immunoge-
nicity and efficacy of replication-deficient viral vector vaccines
after immunization by the tonsillar route and compared them
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to those after systemic administration. Adenoviral vectors were
selected for tonsillar immunizations, assuming that the natural
infection pathway of adenoviruses would also allow efficient
delivery of the vector-encoded vaccine antigens. For priming
we also used a single-cycle immunodeficiency virus vaccine
(SCIV). The SCIVs were produced by transient transfection of
an SIV genome which was made replication deficient by mu-
tations in the primer binding site and a deletion of vif (23). To
allow a single round of replication, the primer binding site
mutations were complemented in trans by a matched tRNA
expression plasmid in vif-independent 293 producer cells. Af-
ter administration to the vaccinees, the SCIVs can undergo
only a single round of replication, leading to the production of
noninfectious virus-like particles in vivo (12, 23). To increase in
vivo expression levels, we pseudotyped the SCIVs with the G
protein of vesicular stomatitis virus, which mediates efficient
entry into a broad spectrum of cells (6), including dendritic
cells (16). After repeated systemic immunizations with SCIVs,
SIV-specific humoral and cellular immune responses were
observed, peak viremia during primary infection with the
SIVmac239 challenge virus was significantly reduced (13, 23),
and in a long-term vaccination experiment persistent suppres-
sion of SIVmac239 viral load was achieved (24).
We now observed that adenoviral vectors delivered by a
simple atraumatic spray procedure onto the tonsils led to ex-
pression of the encoded antigen in close proximity to the in-
ductive site of the MALT. Oral immunization with the adeno-
viral vectors was sufficient to induce cellular and humoral
immune responses to encoded SIV vaccine antigens, but the
adenoviral vector vaccine alone did not reduce challenge virus
load. By contrast, a tonsillar prime-boost regimen of SCIV and
adenoviral vector vaccines induced higher levels of cellular
immune responses and reduced viral RNA levels after chal-
lenge with neutralization-resistant SIVmac239.
MATERIALS AND METHODS
Preparation of the vaccines. 293T (293ts/A1609) (10), 293A (strongly adherent
subclone of 293, Quantum Biotechnologies, Montreal, Canada), 293T-Rex (In-
vitrogen, Karlsruhe, Germany), and S-MAGI cells (8) were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal calf serum,
penicillin, streptomycin, and glutamine. The SCIVs were produced by transient
transfection of 293T cells as previously described (23). Viral particles from the
conditioned medium were thereafter concentrated by low-speed centrifugation
(27). The preparation contained 235 g/ml reverse transcriptase as measured by
a commercial reverse transcriptase assay (Roche, Penzberg, Germany). Further
characterization of the SCIV preparation revealed a similar ratio of Gag and Env
bands in Western blot analyses as previously reported (23) and readily detectable
levels of vesicular stomatitis virus G. For determination of the infectious titer,
S-MAGI indicator cell lines, containing the beta-galactosidase gene downstream
of the human immunodeficiency virus type 1 long terminal repeat, were seeded
at a density of 2.5  104 cells per well of a 24-well plate. One day later, 200 l
of serial dilutions of the concentrated SCIV particles were incubated with the
S-MAGI cells for 3 hours prior to addition of fresh medium. Two days later,
S-MAGI cells were stained with 5-bromo-4-chloro-3-indolyl--D-galactopyrano-
side (X-Gal) essentially as described previously (8). The vector titer was calcu-
lated from the number of stained cells per well and was expressed as LacZ-
forming units/ml. The two SCIV preparations had infectious titers of 3.5  109
and 2.3  108 infectious units/ml. The construction of the recombinant adeno-
viral vector expressing the codon-optimized SIV Gag-Pol (Ad-Sgpsyn) has been
described previously (25). For the construction of the recombinant adenovirus
expressing the SIV envelope (Ad-Senv-co), a codon-optimized version of the
SIVmac239 envelope gene encoding a membrane-anchored Env with a truncated
(amino acids 733 to 879) C terminus of the cytoplasmic domain (TM207) (41)
was cloned into the HindIII-XbaI-digested pShuttle-TetO2 (25), generating pS-
Senv-co. The leader peptide of SIV was replaced by the leader peptide of tissue
plasminogen activator. The full-length adenoviral vector plasmid was generated
by homologous recombination of the plasmids pS-Senv-co and pAdEasy1 (21) in
BJ5183 cells (Stratagene, Amsterdam, The Netherlands) using standard proce-
dures. Correctly recombined plasmids were transfected into 293T-Rex cells, and
the recombinant viral vectors growing out from the transfected cells were ana-
lyzed for expression of the vaccine antigen by Western blot analyses. A second
adenoviral vector (Ad-Srtenvco) encoding Rev and a secreted version of SIV Env
was constructed in pShuttle-CMV by deleting the transmembrane domain of
Env. The construct contains SIVmac239 nucleotides 6696 to 6859 (first exon of
rev; numbering is according to GenBank entry M33262), the first 25 codons of the
tissue plasminogen activator leader sequence, SIVmac239 env codons 23 to 683
in a codon-optimized version, and wild-type SIV nucleotides 9002 to 9499
(codons 715 to 879 of SIV env and second exon of rev). Full-length adenoviral
vector constructs were generated by homologous recombination with pAdEasy1,
and vector stocks were produced in 293 cells as described above. After purifica-
tion of adenoviral vectors by CsCl gradient centrifugation, the particle concen-
tration was measured by the optical density. The adenoviral vaccine preparations
of Ad-Sgpsyn, Ad-Senvco, and Ad-Srtenvco had particle concentrations of 4.9 
1012/ml, 4.8  1012/ml, and 2.4  1012/ml, respectively. The Ad-GFP vector was
kindly provided by Kirsten Bender (Bochum) and had been constructed by
homologous recombination using the pAdTrack-CMV plasmid and pAD-Easy1
(21). For the adenoviral neutralization assay, a second adenoviral vector, desig-
nated Ad-EGFP, was generated by cloning the enhanced green fluorescent
protein (EGFP) gene of pEGFP-1 (Clontech, Mountain View, CA) into
pShuttle-CMV (Qbiogene, Irvine, CA) and subsequent homologous recombina-
tion with pAD-Easy1.
Animal experiments. Thirty-four purpose-bred young adult rhesus macaques
were used in the present studies. Twenty-two of them were of Indian origin, and
the 12 monkeys for the second immunization experiment had been imported
from China. Animals were housed at the German Primate Centre, and animal
care and use were in compliance with the German Animal Protection Law and
relevant institutional guidelines.
Just prior to oral immunization, animals were treated intravenously with gly-
copyrroniumbromide at a dose of 40 g. In the “Ad-oral” experiment, Ad-Sgpsyn
and Ad-Senvco were each adjusted to a final concentration of 2  1011 parti-
cles/ml and administered in a total volume of 0.5 ml. In the prime-boost exper-
iment, the adenoviral vectors Ad-Sgpsyn and Ad-Srtenvco were administered by
oral spray immunization (0.5-ml total volume) or intramuscular immunization
(final volume of 3 ml injected at five different sites) at doses of 0.5  1011 and 3 
1011 particles per construct, respectively. For intravenous immunization with
SCIV, 2  109 LacZ-forming units were injected in a final volume of 10 ml.
Challenge virus exposure was performed with pathogenic SIVmac239 by the
tonsillar route by touching the tonsils lightly with a cotton-wool swab soaked with
culture medium containing approximately 6,000 median tissue culture infectious
doses of cell-free SIVmac239 virus as described previously (24).
Immunohistochemistry and in situ hybridization. (i) Routine histology. The
tissues obtained by biopsy or autopsy were divided into two parts. One part was
fixed overnight in 4% neutral buffered formalin and embedded in paraffin. The
sections were stained with hematoxylin and eosin and Giemsa stain for routine
histology. Portions of the fresh tissue were embedded in tissue freezing medium
(Leica, Nussloch, Germany), snap frozen in liquid nitrogen, and stored at 70°C
until use.
(ii) Immunohistochemistrty. The staining for the detection of GFP was per-
formed on frozen sections. The cryostat sections were fixed with acetone for 30
min and then incubated with rabbit polyclonal antibody GFP-Ch1P (1:300; Ab-
cam, Cambridge, United Kingdom) at room temperature for 30 min. The anti-
body binding was visualized after incubation of the sections with a biotinylated
goat anti-rabbit immunoglobulin (DakoCytomation, Copenhagen, Denmark)
followed by streptavidin-APAAP (Dako). The color was developed with the
alkaline phosphatase anti-alkaline phosphatase technique with New Fuchsin as
red chromogen.
(iii) In situ hybridization. SIV RNA in the axillary lymph nodes was detected
on paraffin sections with a 35S-labeled single-stranded (antisense) RNA probe
(Lofstrand Laboratories, Gaithersburg, MD) as described in detail before (39).
From each biopsy, six to eight sections were hybridized. Spleen sections from
naive infected monkeys were used as a positive control. As a negative control,
sections from each lymph node specimen were hybridized with a sense-strand
35S-labeled probe. The slides were dipped in photo emulsion (NBT2; Kodak) and
exposed in the dark at 4°C for 7 days. The slides were developed (D19; Kodak),
fixed, counterstained with hematoxylin, and mounted. Examination of the sec-
tions was performed with a Zeiss Axiophot microscope (Carl Zeiss, Jena, Ger-
many) equipped with transmission and epiluminescent illumination. Cells ex-
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pressing SIV RNA were counted in all sections, and the mean value per section
was calculated.
Immune monitoring and viral load measurement. To determine SIV-specific
T-cell responses, a gamma interferon (IFN-) enzyme-linked immunospot
(ELISPOT) assay was employed essentially as described previously (37). The
following antigenic stimuli were used: a 20-mer peptide pool of the SIVgag p27
region (EVA ARP714.1 to -22; 22 peptides), a pool of 15-mer peptides of
SIVmac251/32H-Gag (EVA7066.1 to -16; 16 peptides), a pool of 15-mer pep-
tides of SIVmac251/32H-Rev (EVA7068.1 to -8; 8 peptides), and four pools of
15-mer peptides of SIVmac239 Env (NIH AIDS Research & Reference Reagent
Program, catalog no. 62049) comprising 55 or 56 peptides each (overall, 218 Env
peptides). As an SIV-unrelated control stimulus, a pool of six 20-mer peptides
derived from the gHCV NS3 gene (amino acids 1138 to 1157, 1198 to 1217, 1208
to 1227, 1458 to 1477, 1528 to 1547, and 1538 to 1557) was applied.
To measure humoral SIV-specific immune responses, a standard enzyme-
linked immunosorbent assay for the detection of antibodies against the SIV
polypeptides gp130 SU and p27 CA (36a) in a limiting-dilution format and a
yield reduction assay for the determination of neutralizing antibodies (24) were
employed. Recombinant SIVgp130 (EVA670, NIBSC) and SIVp27 (EVA643)
for enzyme-linked immunosorbent assay were kindly provided by Programme
EVA.
Adenovirus-neutralizing antibodies known to be induced in vaccination re-
gimes employing adenoviral vectors were determined in a green fluorescent focus
reduction assay as previously described (14) with slight modifications. Briefly,
inactivated monkey sera were analyzed in serial fourfold dilutions starting at a
1:8 dilution. A 120-l portion of diluted serum and 100 l of a replication-
deficient Ad5 vector expressing EGFP containing 2  105 PFU were incubated
in triplicates at 4°C for 2 h. Then, 150 l of this mixture was transferred onto
96-well flat-bottom plates which had been preseeded with 293 cells, and the
plates were incubated at 37°C with 5% CO2 for 2 days. Thereafter the plates were
examined under a fluorescence microscope. Sample dilutions exhibiting 50%
reduction of green fluorescent foci compared to infected controls incubated with
autologous monkey sera obtained before immunization were considered positive
for Ad5 neutralizing antibodies. Viral RNA copy numbers in plasma were de-
termined by real-time PCR as described previously (38).
Statistical analyses. The mean number of spots per 106 peripheral blood
mononuclear cells was determined from triplicate cultures for each peptide pool,
and the mean number of spots in control cultures with an irrelevant hepatitis C
virus peptide pool or lacking a peptide was subtracted. If data from several time
points during the same treatment period (e.g., prior to immunization or after the
first, second, or third immunization) were available, the mean ELISPOTs were
calculated for this period for each peptide pool and each animal. The mean and
standard deviation from each treatment period were determined for all animals
and each peptide pool within the same group. A one-way analysis of variance
(ANOVA) followed by pairwise multiple comparison using the Tukey test was
performed for each peptide pool to test whether there is a significant difference
in the ELISPOTs prior to immunization and after each immunization. Signifi-
cantly enhanced ELISPOT responses during immunization within a treatment
group were compared to the control group using the two-sided t test. The t test
(two sided) was also used to analyze differences in the peak viral load, early set
point RNA levels (mean from weeks 16, 20, and 24 for each animal), and late set
point RNA levels (means from weeks 28 to 48). The Mann-Whitney rank sum
test was used to evaluate differences in the median values of the log2 antibody
titers.
RESULTS
Adenoviral vector immunization by the tonsillar route.
Given the tropism of adenoviruses of subgenus C for the upper
respiratory tract and their persistence in submucosal lymphatic
tissues, we first analyzed whether a replication-deficient adeno-
viral vector would allow expression of vaccine antigens in close
proximity to the oral MALT. A replication-deficient adenoviral
vector expressing GFP was therefore sprayed directly onto the
tonsils of four rhesus monkeys. The adenoviral vector was
administered at a concentration of 2  1011 particles/ml in
total volume of 0.5 ml using a spray pump system (Pfeiffer,
Radolfzell, Germany). Since ketamine anesthesia induced hy-
persalivation, monkeys were treated with glycopyrroniumbro-
mide 10 to 15 min prior to the oral spray application, in order
to enhance access of the vector preparations to the lympho-
epithelium of the tonsils. Two days later, immunohistological
staining revealed GFP-positive cells with epithelial cell-like
morphology at the basal cell layer of the squamous epithelium
of the tonsils in three of four animals. The close proximity to
cells with lymphoid morphology (Fig. 1A and B) suggests that
antigens could be delivered atraumatically to the induction site
of the oral MALT by adenoviral vector immunization through
the tonsillar route.
To explore whether oral immunization with replication-de-
ficient vectors would indeed elicit immune responses, 10 rhesus
monkeys received two doses of an adenoviral vector vaccine at
weeks 0 and 4 by oral spray immunization (Fig. 2A). The SIV
adenoviral vector vaccine consisted of two adenoviral vectors
expressing gag-pol and env, respectively. Four weeks after the
first immunization, low antibody titers against Env and Gag
were detected in a minority of immunized monkeys (Fig. 2B).
After the second immunization, significantly higher antibody
titers to p27CA (Mann-Whitney rank sum test, P  0.009) and
gp130 (P 	 0.001) than those prior to immunization were
observed. Four of the 10 animals received a third oral immu-
nization with the same adenoviral vector vaccine at week 16.
After the third immunization, Env antibody titers increased
significantly (P  0.023), while the increase in the Gag anti-
body titers did not reach statistical significance.
Different overlapping peptide pools spanning Gag and Env
of SIV were used in an IFN- ELISPOT assay to monitor
cellular immune responses after immunization (Fig. 2C). Since
Rev is not encoded by the vaccines used, a Rev peptide pool
was also included as a negative control. To avoid arbitrary
definitions of thresholds for ELISPOT positivity, which could
bias statistical analyses, the ELISPOT values of nonstimulated
control cultures of each monkey at each time point were sub-
tracted from the values obtained after stimulation with differ-
ent overlapping peptide pools. In nonimmunized animals and
in animals prior to immunization, this led to low positive or
negative values, depending on the peptide pools added, sug-
gesting either weak unspecific stimulatory and inhibitory ef-
fects or random variation. For further statistical analyses, the
mean of the ELISPOT response measured prior to immuniza-
tion (weeks 4 and 0) was compared to the mean of the
ELISPOT response at weeks 2 and 4 and at weeks 6 and 8 in
order to determine the effect of the first and second adenoviral
vector immunizations, respectively. Since the dynamics of the
immune responses in individual animals were rather heteroge-
neous, with different animals showing the strongest ELISPOT
responses at different time points after immunization, the av-
erage of the results from both time points analyzed after each
immunization is given. Cellular immune responses could al-
ready be detected by the IFN- ELISPOT assay after a single
oral adenoviral vector immunization, but in contrast to the
antibody response, the second immunization did not boost the
IFN- ELISPOT responses (Fig. 2C). In the four animals that
received a third oral immunization, a booster effect on the
IFN- ELISPOT response (mean of responses at weeks 14 and
16) was observed for the Gag peptide pool.
In the IFN- ELISPOT assay, seven different peptide pools
deduced from SIV genes and consisting of 264 single peptides
were used. To exclude the possibility that the increase in IFN-
ELISPOTs is due to stimulation of T cells originally raised
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against non-SIV antigens by some of the peptides used, non-
immunized control animals were also analyzed in the IFN-
ELISPOT assay. With the exception of the Env3 peptide pool,
no significant differences between the preimmunization values
and the values after mock immunization were detected in the
control group (Fig. 2D). Importantly, the IFN- ELISPOT
response to the Gag, p27, and Env2 peptide pool after the first,
second, and/or third immunization was significantly higher in
the orally immunized than in the nonimmunized group (Fig.
2C). Thus, oral spray immunization with adenoviral vectors
FIG. 1. Detection of replication-deficient viral vectors in the lymphoid tissue. (A and B) GFP expression after tonsillar administration of an
adenoviral vector (Ad-GFP) was detected by immunohistochemistry (red) in the crypt (A) and squamous epithelium (B) of the tonsil. The arrow
(B) points to a large, nonlymphoid cell showing positivity for GFP in the lymphoid tissue. (C) In a control macaque, tonsils were not stained with
the antibody to GFP. (D) As a positive control, 293T cells transfected with a GFP expression plasmid were also stained. (E to H) SCIV-producing
cells in axillary lymph nodes 4 days after intravenous inoculation (E) or tonsillar application (F to H) of the vaccine. Cells expressing SIV RNA
(greenish blue color with the combined reflected light and transillumination) are in the T-dependent zone (E), the germinal center (GC), and the
efferent lymphatic vessel (G and H). This vessel harboring the SCIV-positive cell (G, arrow) is shown with higher magnification (H). The
morphology of the positive cell (H, arrow) demonstrates that it is a lymphocyte (transillumination only; the silver grains are black). The number
of hybridization signals appears low since the silver grains of the signal are located in a higher focal plane than the cells of the tissue section.
Original magnifications: A, C, and E to G, 100; B and H, 160; D, 50.
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FIG. 2. Adenoviral vector immunization by the tonsillar route. (A) Experimental outline. The scale indicates the number of weeks after the first
immunization. The type of vaccine or challenge virus is given above the time line. Four of the 10 monkeys of the Ad-oral group received a third
oral immunization at week 16. (B) Mean titer and standard deviation of antibodies binding p27 CA or gp130 SU in 10 (weeks 0 to 12) and 4 (weeks
16 to 48) macaques of the Ad-oral group. The vertical dotted line in panel B indicates the time of challenge. (C) ELISPOT responses to the
indicated peptide pools in the Ad-oral group were determined 4 and 0 weeks prior to immunization (Pre), and 2 and 4 weeks after the first, second,
and third oral immunization with the adenoviral vector. ELISPOTs of unstimulated control cultures from each time point were subtracted, and
the means for all available time points were used as single Pre, first, second, and third values for each animal. The means and standard deviations
of the Pre, first, second, and third values for all animals after stimulation with the indicated peptide pools are shown. To determine whether there
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induces cellular and humoral immune responses to the en-
coded vaccine antigen.
Challenge of monkeys immunized with adenoviral vectors by
the oral route. The four monkeys receiving three oral immu-
nizations with the adenoviral vector and eight control monkeys
were subsequently challenged orally with the SIVmac239 virus,
a neutralization-resistant molecular clone homologous to the
vaccine antigens. An oral challenge was performed, since this
provides a reliable, truly atraumatic, mucosal infection route
(36). All animals became infected, and peak viremia and set
point RNA levels did not differ significantly between these two
groups (Fig. 2E). Thus, the immune responses induced by oral
immunization with the adenoviral vector did not protect
against subsequent SIV challenge.
Oral prime-boost regimen. To improve efficacy of the ton-
sillar immunization against SIV, we investigated whether a
heterologous prime-boost regimen consisting of a SCIV prime
and adenoviral vector boost would be beneficial. In addition,
we compared oral spray with systemic vaccine application side
by side. One group of four rhesus monkeys (systemic prime-
boost group) was immunized by priming with SCIV at week 0
by the intravenous route and intramuscular boosting with the
adenoviral vectors carrying gag-pol, env, and rev at week 8 (Fig.
3). A second group of four rhesus monkeys (oral prime-boost
group) was immunized exclusively by spraying the vaccine
preparations of SCIV and the adenoviral vectors directly onto
the tonsils of the monkeys (Fig. 3). For the oral vaccination,
each vaccine was given twice to compensate for the lower dose
administered due to volume restrictions. To control for unspe-
cific immunostimulatory effects of the adenoviral vector vac-
cines prior to challenge, two control monkeys each received an
adenoviral vector encoding GFP by either the oral route
(weeks 8 and 12) or the intramuscular route(week 8). All
groups were challenged orally at week 20 with SIVmac239.
Systemic spread of SCIV-transduced cells after oral immu-
nization. We previously observed systemic infection after oral
exposure to replication-competent SIV (36), indicating that
the tonsils provide a port of entry for SIV particles. To explore
whether systemic spread would also occur after oral immuni-
zation with VSV G-pseudotyped replication-deficient SCIVs,
axillary lymph nodes were removed 4 days after immunization
and a highly sensitive in situ hybridization technique was used
to analyze expression of SCIV. A low number of SIV RNA-
positive cells (1.87 RNA-positive cells per section) could be
detected in the lymph nodes of three of the four immunized
animals (Fig. 1E to H). The low number of positive cells did
not allow further characterization of the vaccine-expressing
cells by immunohistochemistry. However, cell morphology in-
dicated that these cells were lymphocytes. The positive cells
were present in the T-cell-dependent zone, the germinal cen-
ters and the sinuses. Importantly, we were able to detect such
cells in the efferent lymphatics. These findings indicate that the
vaccine reached all immunologically important regions of the
node.
Humoral immune responses. Priming with SCIV by the oral
or intravenous route resulted in detectable antibodies to Gag
in only one animal from each group, while Env antibodies were
detectable at low levels in two animals after systemic immuni-
zation (Fig. 4). After the two oral boosts with the adenoviral
vector, an increase in Gag antibody titers was observed in all four
animals, and three of the four animals also developed Env anti-
bodies. After boosting the systemic vaccination group with the
adenoviral vector, a sharp increase in antibody titers was ob-
served, which exceeded those seen after tonsillar immunization
(Fig. 4). The anti-Env antibodies induced in the systemic vacci-
nation group were able to neutralize the SIVmac251 strain, which
had been used in the neutralization assay due to the neutraliza-
is a statistically significant difference between the means of the Pre, first, and second, ELISPOT values for each peptide, one-way ANOVA was
used, followed by pairwise multiple comparison using the Tukey test. Numbers above the horizontal bars give the respective P values if a significant
difference between two time points was obtained by ANOVA. Columns marked with an arrow indicate ELISPOT responses that are significantly
higher (P 	 0.05, t test) than the mock ELISPOT response to the respective peptide pool of the Ad-control group (D). For the 4 of the 10 animals
that received a third oral immunization, a paired t test (#) was used to determine significant increases in ELISPOT responses between the second
and third immunizations. (D) IFN- ELISPOT responses in six control animals were determined weeks 4, 0 (Pre), and 8 (mock) as described
in for panel C. The t test was used to determine statistically significant differences between the Pre and mock ELISPOT responses for each peptide.
*, due to failure of the equal variance test, ANOVA on ranks followed by pairwise comparison using Dunn’s method was performed. (E) RNA
load after challenge with SIVmac239. The mean and standard deviation of the viral RNA loads in the four animals receiving three oral adenoviral
vector immunizations (Ad-oral) and in eight control monkeys infected in parallel are shown.
FIG. 3. Prime-boost (p/b) immunization with viral vector vaccines.
The different treatment groups and number of animals per group are
given. The scale indicates the number of weeks after the first immu-
nization. The type of vaccine or challenge virus, route of immunization,
and dosages are given above the time line. tons, tonsillar; i.v., intrave-
nous; i.m., intramuscular.
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tion-resistant phenotype of the SIVmac239 virus, while neutral-
izing antibodies in the oral prime-boost group remained unde-
tectable (data not shown).
Cellular immune responses. Cellular immune responses after
immunization were monitored using the IFN- ELISPOT assay
(Fig. 5). For statistical analyses, the mean of the ELISPOT re-
sponse measured prior to immunization (weeks 4 and 0) for
each group was compared to the mean of the ELISPOT response
measured after priming (weeks 4 and 8) and boosting (weeks 10
and 12). After oral priming with SCIV, the ELISPOT response to
the various peptide pools did not exceed the background response
seen prior to immunization. However, after the first boost with
the adenoviral vectors by the oral route, a significant increase in
the IFN- ELISPOT responses after stimulation with the p27 and
Env3 peptide pools was observed (Fig. 5A). Although consider-
ably higher mean ELISPOT numbers after boosting were also
seen by stimulation with the other peptide pools, this increase did
not reach statistical significance. The systemic prime-boost regi-
men induced a broad IFN- ELISPOT response to Gag, Rev, and
various Env peptide pools (Fig. 5B). Side by side with the vacci-
nated animals, ELISPOT responses were also measured for the
control monkeys (Fig. 5C). With one exception, there were no
significant differences between the boost values obtained for the
control group and its prevaccination values, excluding the possi-
bility that a systematic error due to variations in culture condi-
tions is responsible for the positive ELISPOT responses seen
after boosting in the vaccinated animals. A significant change in
the ELISPOT response of the control group was observed only
for the Env3 peptide pool after priming, suggesting fluctuation of
T cells cross-reacting with a peptide of the Env3 peptide pool.
FIG. 4. Antibody titers to SIV p27 CA (left panels) and gp130 SU (right panels) after oral or systemic immunization and in control monkeys.
The five-digit numbers are monkey designations, and arrows mark the time points of immunization. The vertical dotted lines indicate the time of
challenge. p/b, prime-boost.
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Nevertheless, the increase in the Env3 IFN- ELISPOTs in the
immunized groups seems to be vaccine induced, since the number
of ELISPOTs after boosting was significantly lower in the control
group than in the immunized groups. The ELISPOT response to
the p27CA peptide pool after the oral booster immunization was
also significantly higher than the ELISPOT response measured in
parallel for the control group. Thus, the ELISPOT response to
these peptide pools after the oral prime-boost immunization is
significantly higher than the preimmunization values of the same
group and the ELISPOT responses measured in parallel in the
nonimmunized control group. Using the same criteria for the
systemic SCIV prime-adenoviral vector boost immunization, a
broader reactivity was observed (Fig. 5B), with only two peptide
pools not showing a statistically significant ELISPOT response.
Viral load after challenge. To investigate the efficacy of the
oral prime-boost vaccination approach, monkeys were chal-
lenged with SIVmac239 by the tonsillar route, thus providing a
mucosal challenge with a stringent form of SIV. All animals
became infected (Fig. 6), but peak viral RNA loads (week 2),
early-set-point RNA levels (mean viral RNA load at weeks 12
to 24), and late-set-point RNA levels (mean viral RNA load at
weeks 28 to 48) were 83-, 35-, and 43-fold lower, respectively,
in orally immunized monkeys than in the control animals. The
differences in peak viral load between the two groups were
statistically significant (P 	 0.05). Of note, no differences in
viral load levels were observed between orally and systemically
immunized monkeys.
Neutralizing antibodies against adenovirus. Antibody titers
to SIV after oral immunization with the adenoviral vector
vaccine increased after the second administration (Fig. 2). This
implies that oral immunization with adenoviral vectors does
not prevent expression of the vaccine antigen after a second
dose of the same adenoviral vector. Since it has been previ-
ously observed that intramuscular immunization with adeno-
viral vector vaccines limited the efficacy of booster immuniza-
tion with homologous adenoviral vectors, we compared
induction of neutralizing antibodies to the adenoviral vector
after oral and intramuscular (systemic) immunization (Fig. 7).
A single intramuscular injection of 6  1011 adenoviral vector
particles induced antibody titers exceeding 1/100 in all mon-
keys (Fig. 7B). In contrast, a single oral immunization with 1 
1011 or 2  1011 particles did not induces neutralizing antibod-
ies, although high-titer neutralizing antibodies were detected
after the oral booster immunization with the adenoviral vector
(Fig. 7A and B). However, the neutralizing antibody titers
declined rapidly. A third oral immunization with the adenovi-
ral vectors 12 weeks after the second clearly boosted humoral
immune responses to SIV antigens, indicating that neutralizing
antibodies to the adenoviral vector did not prevent expression
of the vaccine antigen after repeated oral administration.
DISCUSSION
Simple spraying of replication-deficient adenoviral vectors
onto the tonsils either alone or after priming with SCIV in-
duced cellular and humoral immune responses to the encoded
vaccine antigens, indicating that the viral vectors can overcome
the epithelial barrier, deliver the vaccine antigen to the induc-
tive sites of the MALT, and avoid the induction of tolerance
frequently observed after oral delivery of protein antigens.
Viruses have evolved mechanisms to transit tight cell layers by
a cellular transcytosis pathway without replicating in the cells
they pass (1, 5, 22, 31, 34). Since even enveloped viruses are
shuttled in this way through the cell and secreted at the baso-
lateral site in an infectious form, transduction of basal cell
layers by viral vector vaccines seems possible. In addition, the
lymphoepithelium in the depth of the tonsillar crypts with its
interspersed M cells should facilitate uptake of antigens. Fol-
lowing oral SCIV application, we could detect SIV RNA-pos-
FIG. 5. IFN- ELISPOT response after prime-boost immunization by
the oral (A) or systemic (B) route. ELISPOT responses to the indicated
peptide pools were determined 1 and 3 weeks prior to immunization
(Pre), at weeks 4 and 8 (prime), and at weeks 10 and 12 (boost).
ELISPOT responses are presented as described in the legend to Fig. 2.
Numbers above the horizontal bars give the respective P values if a
significant difference between two time points was obtained by ANOVA.
Columns marked with an arrow indicate that the ELISPOT response is
significantly higher (P 	 0.05, t test) than the ELISPOT response to the
respective peptide pool of the control group at the same time point (C).
*, due to failure of the normality test, ANOVA on ranks followed by
pairwise comparison using Dunn’s method was performed. PBMC, pe-
ripheral blood mononuclear cell.
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itive cells in nondraining lymph nodes. The localization of the
SIV RNA-positive cells in the sinuses of the lymph nodes and
the efferent lymphatics suggests that SCIV-infected cells carry
the viral vector vaccines through out the lymphatic tissues.
Although we cannot formally exclude replication of SCIV in
vivo, we consider this to be highly unlikely since (i) the primer
complementation approach used to generate the SCIVs re-
duces infectivity in single-round replication assays at least 104-
fold (17, 18); (ii) the SCIVs have an additional deletion of vif,
which severely impairs replication in primary cells and rhesus
macaques (9, 32), and (iii) we were never able to recover
replication-competent virus from SCIV-injected animals de-
spite repeated attempts (23).
For the adenoviral vector vaccine, we provide evidence of
transduction of cells with epithelial cell-like morphology at the
basal layer of the squamous epithelium. The close proximity of
the transduced cells to lymphoid cells suggests that the tonsil-
lar spray immunization indeed leads to atraumatic delivery of
vaccine antigen to the oral MALT. The detection of adenoviral
vector-transduced cells underneath intact superficial layers of
the squamous epithelium provides the first in vivo evidence for
transcytosis of adenoviral particles through these superficial
layers.
Another atraumatic route used for immunization has been
nasal application. Although the nasal MALT might be well
suited for induction of immune responses, the anatomic link
between nose and brain via the olfactory nerve suggests a note
of caution particularly for the use of viral vector vaccines, since
retrograde axonal transport of viral capsids has been well doc-
umented (15, 26).
Oral spray immunization with the adenoviral vectors alone
also revealed induction of humoral and cellular immune re-
sponses. While the oral booster immunization with the adeno-
viral vectors 4 weeks after priming enhanced humoral immune
FIG. 6. RNA load after challenge. (A) The means and standard deviations for the three groups are shown. (B to D) The viral RNA loads in
monkeys immunized orally (B) or systemically (C) and in the nonimmunized control group (D) are shown for each of the macaques. The five-digit
numbers are monkey designations. p/b, prime-boost.
FIG. 7. Neutralizing antibodies to the adenoviral vector. (A) Neu-
tralizing antibody titers to the adenoviral vector before the first (Pre)
and third (pre 3rd) and 2 weeks after the first, second, and third
adenoviral vector applications (dose, 2  1011 particles) by the tonsillar
route (for the immunization regimen, see Fig. 2A). (B) Neutralizing
antibody titers to the adenoviral vector were determined before (Pre)
and 4 weeks after the first (prime) and second (boost) adenoviral
vector applications by the tonsillar (oral; dose, 1  1011) or intramus-
cular (systemic; dose, 6  1011) route. The two control macaques
receiving Ad-GFP either orally of systemically (for the immunization
regimen, see Fig. 3A) were included in the analyses. The means and
standard deviations for each group are shown.
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responses, ELISPOT responses were not increased by this
early boost. Since a third oral booster immunization with the
adenoviral vector seemed to stimulate humoral and cellular
immune responses, a longer time period between immuniza-
tions might be beneficial. However, the number of animals
responding to the oral adenoviral vector immunization alone
was lower than that after the prime-boost regimen. This sug-
gests that the SCIV given orally primed for immune responses,
although anti-SIV responses were mostly not detectable until
after the adenoviral vector booster immunization. Since SIV-
specific immune responses induced by adenoviral vector vac-
cines might inhibit the infectivity of the SCIV, the SCIVs, and
not the adenoviral vectors, were used for priming.
Preexisting immunity to the vector could limit the use of
adenoviral vectors in humans (40). In addition, neutralizing
antibodies induced by priming with adenoviral vectors reduce
the efficacy of booster immunizations with the same adenoviral
vector serotype (3). We therefore compared induction of neu-
tralizing antibodies to the adenoviral vector after oral and
intramuscular immunizations. While a single intramuscular in-
jection of the adenoviral vector vaccine induced neutralizing
antibodies, substantial neutralizing antibodies to the adenovi-
ral vector were observed only after two oral immunizations.
Consistently, a strong booster effect of the second oral adeno-
viral vector immunization was evident, as humoral immune
responses to the vector-encoded vaccine antigens were ob-
served only after the second oral adenoviral vector immuniza-
tion. Even a third oral adenoviral vector immunization given
12 weeks after the second boosted immune responses to the
vaccine antigens in four out of four monkeys, suggesting that
repeated administration of the same adenoviral vector is fea-
sible for the oral immunization route. A rapid decline in neu-
tralizing antibody titers to the adenoviral vector might explain
the booster effects observed after the third oral adenoviral
vector immunization. In addition to extended waiting periods
between booster immunizations, recent advances with chimeric
adenoviruses and/or the use of vectors based on adenovirus
serotypes with low prevalence should also be able to overcome
potential problems of oral adenoviral vector immunization
with preexisting immunity in humans (reviewed in reference 2).
In addition to the immunogenicity of the oral SCIV prime-
adenoviral boost immunization, we also observed substantial
suppression of viral load after challenge with SIVmac239 in the
absence of a sterilizing immunity. This indicates that oral im-
munization induced systemic immune responses inhibiting SIV
replication. The mechanisms mediating this reduction in viral
load remain to be defined. Neutralizing antibodies to the
SIVmac239 challenge virus could not be detected, and there
was no obvious inverse correlation between the magnitude of
the IFN- ELISPOT responses and the viral load after chal-
lenge. A more detailed characterization of polyfunctional CD4
and CD8 T-cell responses (4, 19) might provide better corre-
lates of protection. Whether the oral prime-boost immuniza-
tion is indeed more efficient than oral immunization with ad-
enoviral vectors alone cannot be concluded with certainty.
While the adenoviral vector vaccine of the first study expressed
a membrane-bound form of SIV Env, the adenoviral vector
vaccine of the second study encoded Rev and a secreted form
of SIV Env. Furthermore, rhesus monkeys of Indian origin
were used in the first study, which are more susceptible to fatal
consequences of SIV infection than the rhesus monkeys of
Chinese origin used in the second study (28). Nevertheless,
given the difficulties in inducing protective immune responses,
particularly against the neutralization-resistant SIVmac239 vi-
rus, a 35- to 83-fold reduction in peak and set-point RNA
levels after oral immunization is a striking observation, even in
rhesus monkeys of Chinese origin.
Interestingly, subtopical delivery of modified vaccinia virus
Ankara vaccines into the palatine tonsils of rhesus macaques
via a needle-free injection device also induced substantial im-
mune responses to the vector-encoded antigens and suppres-
sion of viral load after SHIV89.6P challenge (11). Thus, fur-
ther studies on the efficacy of oral vaccination with viral vector
vaccines against systemic and particularly respiratory tract in-
fections seem warranted.
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